Treatment
| |
Day of study
|
---|
|
9
|
16
|
23
|
30
|
37
|
---|
Placebo
|
Range
|
17–26
|
20–28
|
15–26
|
21–27
|
19–26
|
Arithmetic mean (AM)
|
21.00
|
24.13
|
22.00
|
22.88
|
22.25
|
Geometric mean (GM)a
|
20.79
|
23.98
|
21.69
|
22.80
|
22.15
|
Sarolaner
|
Range
|
0–0
|
0–2
|
0–2
|
0–3
|
0–1
|
Arithmetic mean (AM)
|
0
|
0.38
|
0.50
|
1.25
|
0.25
|
AM Efficacy (%)
|
100
|
98.45
|
97.73
|
94.54
|
98.88
|
G. mean (GM)a
|
0
|
0.25
|
0.32
|
1.03
|
0.19
|
GM Efficacy (%)
|
100
|
98.95
|
98.54
|
95.48
|
99.15
|
Test statistic vs placebo
|
t
(19) = 54.50
|
t
(25) = 20.30
|
t
(19) = 13.13
|
t
(23) = 12.78
|
t
(26) = 21.67
|
P-value vs placebo
|
< 0.0001
|
< 0.0001
|
< 0.0001
|
< 0.0001
|
< 0.0001
|
Afoxolaner
|
Range
|
0–0
|
0–1
|
0–4
|
0–2
|
0–1
|
Arithmetic mean (AM)
|
0
|
0.13
|
1.50
|
0.38
|
0.25
|
AM Efficacy (%)
|
100
|
99.48
|
93.18
|
98.36
|
98.88
|
G. mean (GM)a
|
0
|
0.09
|
1.28
|
0.25
|
0.19
|
GM Efficacy (%)
|
100
|
99.62
|
94.12
|
98.90
|
99.15
|
Test statistic vs placebo
|
t
(19) = 54.50
|
t
(25) = 21.23
|
t
(19) = 10.60
|
t
(23) = 15.29
|
t
(26) = 21.67
|
P-value vs placebo
|
< 0.0001
|
< 0.0001
|
< 0.0001
|
< 0.0001
|
< 0.0001
|
Test statistic vs sarolaner
|
t
(19) = 0.00
|
t
(25) = 0.93
|
t
(19) = 2.53
|
t
(23) = 2.51
|
t
(26) = 0.00
|
P-value vs sarolaner
|
1.0000
|
0.3606
|
0.0204
|
0.0195
|
1.0000
|
-
a
P-values are based on comparison of geometric means